Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
i-PHORECAST eplerenone intervention study in presymptomatic PLN R14del carriers
NL-OMON41504Phase 3Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- May 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of eplerenone in phospholamban-associated cardiomyopathy (PLN-CM) and arrhythmogenic cardiomyopathy (ACM) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Composite disease progression endpoint. Started May 2014; status: active, not recruiting.
02
Drugs
eplerenone
03
Conditions
phospholamban-associated cardiomyopathy (PLN-CM)arrhythmogenic cardiomyopathy (ACM)
Beyond the preview
Go deeper on NL-OMON41504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41504.